|
Age
| |
|---|
|
Median (range)
|
57 (30 to 76)
|
|---|
| |
n (%)
|
|---|
|
Menopausal status
| |
|
Premenopausal
|
4 (12)
|
|
Postmenopausal
|
30 (88)
|
|
Primary breast cancer at presentation
|
23 (68)
|
|
Tumor size (cm)
| |
|
1-1.9/2-4.9/≥5/UN
|
3 (13)/14 (61)/2 (9)/4 (17)
|
|
Lymph nodes
| |
|
0/1-3/≥4/UN
|
7 (30)/6 (26)/8 (35)/2 (9)
|
|
Grade
| |
|
II/III/UN
|
8 (35)/11 (48)/4 (17)
|
|
Disease sites*
| |
|
1
|
5 (15)
|
|
2
|
15 (44)
|
|
3
|
5 (15)
|
|
≥4
|
8 (23)
|
|
Unknown
|
1 (3)
|
|
Predominantly visceral disease
| |
|
Yes
|
11 (32)
|
|
No
|
22 (64)
|
|
Unknown
|
1 (3)
|
|
Line of treatment **
| |
|
0
|
18 (53)
|
|
1
|
7 (21)
|
|
≥2
|
9 (26)
|
|
ER/PR status
| |
|
Positive
|
16 (47)
|
|
Negative
|
13 (38)
|
|
Unknown
|
5 (15)
|
|
HER2 status
| |
|
Positive***
|
7 (20)
|
|
Negative
|
23 (68)
|
|
Unknown
|
4 (12)
|
- UN = unknown,
- * Numbers correspond to the number of organs involved
- ** Numbers correspond to the number of prior therapies administered for metastatic disease
- *** IHC:3+ or FISH positive
